Navigation Links
Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
Date:12/4/2010

Poster III  
  • Date: Monday, December 6, 6:00 - 8:00 p.m. ET
  • Location: Hall A3/A4 (Orange County Convention Center)
  • Poster Board III-383

  • Sub-Optimal Inhibition of Thrombus Formation by Aspirin (as measured by RTTP analysis) in Primary Thrombocythemia

    • Presenter: Gillian Stephens, Ph.D., Portola Pharmaceuticals
    • Poster Session: Pathophysiology of Thrombosis: Poster II
    • Date: Monday, December 6, 6:00 - 8:00 p.m. ET
    • Location: Hall A3/A4 (Orange County Convention Center)
    • Poster Board III-997

    About Portola Pharmaceuticals, Inc.

    Portola Pharmaceuticals develops innovative therapeutics based on targets with established proofs of concept that are designed to provide significant advances over current treatments for cardiovascular disease and inflammation. The company has global development and commercialization agreements with two of the world's leading pharmaceutical companies collectively valued at about $1 billion in upfront and milestone payments plus double-digit royalties on future sales. Betrixaban, its oral direct Factor Xa inhibitor, is licensed to Merck & Co., Inc., and elinogrel, its competitive, reversible direct-acting i.v. and oral P2Y12 ADP receptor antagonist, is licensed to Novartis Pharma AG. Both are Phase 2 product candidates that have best-in-class features to address the global multi-billion dollar hospital, specialty and chronic care antiplatelet and anticoagulant markets.

    Portola's proprietary pipeline programs are focused on the discovery and development of PRT064445, a novel recombinant protein anticoagulant antidote, known as the Factor Xa inhibitor antidote, to help manage or reverse the bleeding complications in the tens of millions of patients expected to be treated with Factor Xa inhibitors or low-molecular weight heparin worldwide in
    '/>"/>

    SOURCE Portola Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
    2. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
    3. Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders
    4. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
    5. Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
    6. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
    7. Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
    8. Sagent Pharmaceuticals Adds to Its Oncology Portfolio With Launch of Topotecan Hydrochloride for Injection
    9. Sagent Pharmaceuticals Announces FDA Approval of Midazolam Injection, USP
    10. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
    11. Onyx Pharmaceuticals Announces December 2010 Investor Events
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... and BOSTON , January 23, 2015 ... discovery and development company, is delighted to announce that the ... awarded to Miles Congreve (Vice President of Chemistry), ... Malcolm Weir (Chief Executive Officer and co-founder) for ...
    (Date:1/22/2015)... Colo. , Jan. 22, 2015  BiOptix is pleased ... as Vice President of Chemistry and Biochemistry. Scott joins ... Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of ... development. "Scott is a nationally recognized thought ...
    (Date:1/22/2015)... WOODBRIDGE, ON , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics ... company with a focus on Omega-3 therapies for cardiovascular disease ... summary of the Company,s accomplishments in 2014 and its outlook ... Dear Fellow Shareholders, We would like ...
    Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
    ... in Carotid Atherosclerosis, LEXINGTON, Mass., Oct. 24 ... its pivotal clinical trial (PROVIDENCE-1),studying the effect of ... peripheral arterial disease (PAD) will be,presented on November ... late breaker,Scientific Session at the American Heart Association,s ...
    ... Today the National Legal and Policy,Center (NLPC) asked ... for,International Development (USAID) to investigate the possibility that ... groups operating,needle exchange programs for drug users in ... activist George,Soros are recipients of these legally questionable ...
    Cached Medicine Technology:ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting 2ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting 3Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups 2
    (Date:1/22/2015)... Liberty University has received accreditation for its resident ... Council for Accreditation of Counseling & Related Educational Programs ... for Counseling & Family Studies , is under the leadership ... School of Behavioral Sciences. Prior to the formation of the ...
    (Date:1/22/2015)... 22, 2015 The City of West Hollywood hosted ... to commemorate the 42nd anniversary of the Supreme Court decision Roe ... been 42 years since the Roe vs. Wade decision and the ... present as ever,” said City of West Hollywood Councilmember Abbe Land. ...
    (Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release ... for kids with cancer. The Chemo Duck App, available on iTunes ... enjoyable games to help children of all ages living with cancer ... keep kids entertained, educated and at ease while waiting for clinic ...
    (Date:1/22/2015)... (PRWEB) January 23, 2015 VogueQueen is a ... affordable prices and many designers are thrilled to have it ... business announces its new collection of prom dresses for the ... to drive the strategic vision and he focuses on continuing ...
    (Date:1/22/2015)... 23, 2015 Angelweddingdress is a famous wedding ... its customers to follow it on Facebook, Twitter, and Pinterest. ... Day gift. Angelweddingdress draws a lottery every week. , Moreover, ... Feb. 28, 2015. Click Angelweddingdress homepage for more ...
    Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2
    ... October 18, 2011The U.S. health care system scored 64 ... to the third national scorecard report from the Commonwealth ... today. The scorecard finds thatdespite pockets of improvementthe U.S ... best performers in this country, and among other nations. ...
    ... 2011 Family matters, especially when it comes to ... at Wake Forest Baptist Medical Center, researchers found that ... kidney transplants, as compared to Caucasians. , The retrospective ... journal Clinical Transplantation, compared medical records of ...
    ... , TUESDAY, Oct. 18 (HealthDay News) -- Parents of ... chemotherapy rather than pursue supportive end-of-life care, researchers have found. ... choice, the health care professionals treating these very sick children ... alone to alleviate their patients, discomfort, according to the report ...
    ... vaccine developed by researchers at the University of Pennsylvania,s ... veterinary cancer vaccine of its kind that shows an ... lymphoma. The work shows for the first time the ... which could be employed in the treatment of a ...
    ... COLUMBIA, Mo. America,s elderly population will nearly double ... baby boomers enter retirement, concern exists as to who ... have accepted the caregiving responsibilities, but those caregiving roles ... divorce and remarriage than in previous decades. Now, University ...
    ... Denise Mann HealthDay Reporter , TUESDAY, Oct. ... it comes to treating hot flashes and other symptoms ... of hormone replacement therapy using estrogen alone, experts conclude ... therapy should be considered a very reasonable option for ...
    Cached Medicine News:Health News:Commonwealth Fund Commission national health care scorecard: US scores 64 out of 100 2Health News:Commonwealth Fund Commission national health care scorecard: US scores 64 out of 100 3Health News:Commonwealth Fund Commission national health care scorecard: US scores 64 out of 100 4Health News:Commonwealth Fund Commission national health care scorecard: US scores 64 out of 100 5Health News:African-Americans more likely to donate kidney to family member 2Health News:Parents, Doctors Often Differ on Chemo for Incurable Kids 2Health News:Penn researchers demonstrate efficacy of non-Hodgkin's lymphoma vaccine 2Health News:Penn researchers demonstrate efficacy of non-Hodgkin's lymphoma vaccine 3Health News:Relationships more important than genetic ties when deciding who cares for aging family, study finds 2Health News:Hormonal Treatment of Hot Flashes Still OK for Some: Experts 2Health News:Hormonal Treatment of Hot Flashes Still OK for Some: Experts 3
    Standard general retractor system. Fully-adjustable to maintain a low profile in any approach and any patient. Blades can be stacked on top of each other in the operative site....
    These retractors, made of rugged Noryl® resin, are pre-sterilized and packaged singly in double peel-pouches for easy delivery to the sterile surgical field....
    ... abdominal surgery, the Alexis Wound Retractor ... wound from contamination. For open surgery, ... while minimizing the incision size. For ... instrumental in offering retraction and protection ...
    HemoNIR™ is a portable device that measures the ability of apersons blood to carry oxygen by monitoring functional vs. non functional hemoglobin....
    Medicine Products: